GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Tien Liang Biotech Co 4127.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

34.45

+4.24%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Tien Liang Biotech Co

Its shares trade on Taipei Exchange under the ticker 4127.TWO. It has been listed since 14 January 2003. In the fiscal year to 31 December 2025, it reported revenue of TWD 511.8m and a net loss of TWD 10.3m. At that date it held total assets of TWD 1.18bn and shareholders' equity of TWD 474.0m.

Tien Liang BioTech Co. Ltd. engages in the manufacture and sale of Chinese herbal and western medicine. The company is headquartered in Taipei, New Taipei. The company went IPO on 2003-01-14. The firm is also involved in the import, wholesale and retail of western medicines, as well as the manufacture and sales of traditional Chinese medicines. The firm also provides active pharmaceutical ingredients (APIs), biopharmaceuticals and others. The firm distributes its products in domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
14 Jan 2003
Website
tlb.com.tw ↗

Leadership

Pay as last reported

  • Hanshan ZhanChairman of the Board, since 2024
  • Mr. Xicong ShenGeneral Manager, since 1997
  • Bingkun ChenDirector
  • Yihe HuangDirector
  • Chuwei SunDirector
  • Mr. Yiyang DuIndependent Director
  • Meiling JiangIndependent Director
  • Wenfeng XiaoIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Tien Liang Biotech Co Ltd manufactures Chinese herbal and western medicine in Taipei.
  • The company's domestic market distribution ensures stable sales within Taiwan.
  • Tien Liang Biotech offers APIs, biopharmaceuticals, and traditional Chinese medicines.

Weaknesses

  • Tien Liang Biotech's business is limited to the domestic market in Taiwan.
  • The company's product range lacks international expansion beyond Taiwan.
  • Tien Liang Biotech's focus on traditional Chinese medicine may limit growth potential.

Opportunities

  • Tien Liang Biotech can expand its API and biopharmaceutical offerings globally.
  • Growing demand for traditional Chinese medicine in Asia presents new markets.
  • The company can leverage its 2003 IPO to attract international investors.

Threats

  • Competition from international pharmaceutical companies in Taiwan's market.
  • Regulatory changes in Taiwan's pharmaceutical industry could impact operations.
  • Dependence on the domestic market may expose Tien Liang Biotech to local economic fluctuations.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.